Abstract

Although an influenza vaccine has been available for 70 years, influenza virus still causes seasonal epidemics and worldwide pandemics. Currently available vaccines elicit strain-specific antibody (Ab) responses to the surface haemagglutinin (HA) and neuraminidase (NA) proteins, but these can be ineffective against serologically-distinct viral variants and novel subtypes. Thus, there is a great need for cross-protective or “universal” influenza vaccines to overcome the necessity for annual immunization against seasonal influenza and to provide immunity to reduce the severity of infection with pandemic or outbreak viruses. It is well established that natural influenza infection can provide cross-reactive immunity that can reduce the impact of infection with distinct influenza type A strains and subtypes, including H1N1, H3N2, H2N2, H5N1, and H7N9. The key to generating universal influenza immunity through vaccination is to target functionally-conserved regions of the virus, which include epitopes on the internal proteins for cross-reactive T cell immunity or on the HA stem for broadly reactive Ab responses. In the wake of the 2009 H1N1 pandemic, broadly neutralizing antibodies (bnAbs) have been characterized and isolated from convalescent and vaccinated individuals, inspiring development of new vaccination techniques to elicit such responses. Induction of influenza-specific T cell responses through vaccination has also been recently examined in clinical trials. Strong evidence is available from human and animal models of influenza to show that established influenza-specific T cell memory can reduce viral shedding and symptom severity. However, the published evidence also shows that CD8+ T cells can efficiently select immune escape mutants early after influenza virus infection. Here, we discuss universal immunity to influenza viruses mediated by both cross-reactive T cells and Abs, the mechanisms of immune evasion in influenza, and propose how to counteract commonly occurring immune-escape variants.

Highlights

  • Immunization is the most cost effective public health measure to prevent the spread of infectious diseases

  • Whilst live attenuated influenza vaccine (LAIV) has increased protection compared to trivalent influenza vaccine (TIV) (Monto et al, 2009), TIV has much wider use due to a greater number of manufacturers and constrained use of LAIV in the elderly and very young

  • In vitro studies demonstrated that influenza-infected cells express low levels of NP on their surface (Virelizier et al, 1977; Yewdell et al, 1981), which may enable NP recognition by immune effectors, or alternatively, it is possible that NP-specific Abs are internalized and interrupt virus replication

Read more

Summary

Introduction

Immunization is the most cost effective public health measure to prevent the spread of infectious diseases. There is evidence from animal models that TIV vaccination can inhibit the induction of cross-reactive T cell responses (Bodewes et al, 2011), which require active virus replication, resulting in a greater susceptibility to subsequent infection by novel viruses such as H5N1 (Bodewes et al, 2010).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call